Wedbush analysts believe Tesla (NASDAQ:TSLA) CEO Elon Musk's unsolicited $97.4 billion bid for OpenAI's controlling nonprofit is unlikely to succeed but is intended to slow down the company's ...

Wedbush raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $81 from $77 and keeps an Outperform rating on the shares following the Food and Drug Administration’s approval for ...

Wedbush Securities views recent results from Palantir Technologies (NASDAQ:PLTR) and Salesforce (NYSE:CRM) as proof that artificial intelligence is reshaping the software industry. "The AI ...

Wedbush analyst M. Bryson now forecasts that the semiconductor producer will post earnings of $0.92 per share for the quarter, down from their previous estimate of $1.05.

Read Our Latest Research Report on MCD McDonald’s Stock Up 0.6 % MCD opened at $310.16 on Monday. McDonald’s has a 12-month low of $243.53 and a 12-month high of $317.90. The firm has a market ...

In a new lawsuit filed Monday, Sean "Diddy" Combs has been accused of sexually assaulting a man in 2022. The alleged victim, filing anonymously through attorney Tony Buzbee as John Doe ...

Sean “Diddy” Combs is suing NBC Universal and its streaming service, Peacock, and Ample Entertainment, accusing them of defaming him in a documentary that ties him to crimes more heinous than ...

Sean ‘Diddy’ Combs is suing NBC Universal over a documentary that he says falsely accuses him of being a serial murderer who had sex with underage girls as he awaits trial on federal sex ...

Wedbush said Palantir Technologies (NASDAQ:PLTR) and Salesforce (NYSE:CRM) remain the two best software plays on the AI Revolution for 2025. Analysts led by Daniel Ives said, "Palantir has been a ...

Wedbush initiated coverage of MannKind (MNKD) with an Outperform rating and $11 price target Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing ...

Kura Oncology, Inc. (NASDAQ:KURA – Free Report) – Stock analysts at Wedbush issued their FY2029 earnings estimates for Kura Oncology in a note issued to investors on Thursday, February 6th.

Wedbush raised the firm’s price target on Replimune (REPL) to $19 from $16 and keeps an Outperform rating on the shares. Published first on TheFly – the ultimate source for real-time, market ...